Physician profile
Lauren Gluck
NPI 1033524780
$80,506.94
in general payments reported to CMS, 2019-2025
22 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $342 · 2021: $1,947 · 2022: $14K · 2023: $14K · 2024: $22K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Food and Beverage: $9,827 · Travel and Lodging: $3,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,349.63 |
| Food and Beverage | $9,826.80 |
| Travel and Lodging | $3,487.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $20,707.47 | 2019-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $15,073.36 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $14,834.22 | 2023-2025 | |
| Amgen INC. | $13,714.67 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $4,654.74 | 2019-2025 | Ultomiris, Soliris |
| Genentech, INC. | $2,541.21 | 2022-2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $2,493.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,381.00 | 2023-2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $1,154.08 | 2021-2022 | |
| Genzyme Corporation | $1,039.21 | 2021-2025 | |
| Biogen, INC. | $1,029.62 | 2019-2025 | Tysabri, Vumerity |
| Celgene Corporation | $782.49 | 2022-2023 | Zeposia |
| Abbvie INC. | $446.48 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $176.65 | 2019-2020 | |
| Horizon Therapeutics Plc | $172.98 | 2021-2023 | Uplizna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $153.12 | 2024 | Purified Cortrophin Gel |
| Allergan, INC. | $47.66 | 2019-2020 | |
| Lilly USA, LLC | $24.74 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $21.89 | 2025 | Ponvory |
| Axsome Therapeutics, INC. | $21.37 | 2025 | Symbravo |
| Cycle Pharmaceuticals INC | $21.28 | 2025 | Bafiertam, Tascenso Odt |
| Tonix Medicines, INC. | $15.19 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Gluck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.